ipamorelin clinical trial safety adverse events What should we report? Lessons learnt from the development and implementation of serious event reporting procedures in non-pharmacological trials in palliative care | BMC Palliative Care Immune-related adverse events associated with

Georgakis GV, Li Y, Robin H, Andreeff M , Susan O, Albert V, Younes A

doi: 10.1042/BSR20202924 25 FengXWangSSunZDongHYuHHuangMet al

Proc Natl Acad Sci USA 2013

Treatment Options for Alopecia Areata We understand that each individuals experience with Alopecia Areata is unique

Have you been intending to opt for an advanced treatment to turn your dull skin into flawless skin

Disclosures: Peyton Classon: Nothing to Disclose, Sophia Jaramillo: Nothing to Disclose, Danielle Carlson: Nothing to Disclose, Irene Yan: Nothing to Disclose, Sumera Ilyas: Astrazeneca: Consultant, Rory Smoot: Nothing to Disclose, Gregory Gores: Nothing to Disclose, Tushar Patel: Nothing to Disclose, Davide Povero: Nothing to Disclose 1831 T CELL RECEPTOR AND IMMUNE GENE EXPRESSION PHARMACODYNAMICS FOR DURVALUMAB MONOTHERAPY AND IN COMBINATION WITH TREMELIMUMAB OR BEVACIZUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC) Robin Kate Kelley 1 Young Lee 2 James Conway 2 John Kurland 2 Alejandra Negro 2 Patricia McCoon 3 , 1 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA, 2 Oncology R&D, AstraZeneca, Gaithersburg, MD, USA, 3 Oncology R&D, AstraZeneca, Waltham, MA, USA Background: Study 22 (NCT02519348), a Phase 2 trial of immune checkpoint inhibitor (ICI) monotherapy and combination regimens in uHCC, showed higher rates of objective response (ORR) with STRIDE (Single Tremelimumab [T] Regular Interval Durvalumab [D]) or D+bevacizumab (B) than with D